Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Open-label Safety Trial of PH94B Nasal Spray in the Acute Treatment of Anxiety in Adult Subjects With Social Anxiety Disorder (SAD)

X
Trial Profile

A Phase 3 Open-label Safety Trial of PH94B Nasal Spray in the Acute Treatment of Anxiety in Adult Subjects With Social Anxiety Disorder (SAD)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fasedienol (Primary)
  • Indications Anxiety disorders; Social phobia
  • Focus Adverse reactions; Registrational
  • Acronyms PALISADE Long-term Safety Study
  • Sponsors VistaGen Therapeutics
  • Most Recent Events

    • 07 Nov 2023 According to a Vistagen media release, data from this trial will be presented at the 2023 Neuroscience Education Institute (NEI) Congress.
    • 01 Jun 2023 According to a VistaGen Therapeutics media release, data from this study were presented at American Society for Clinical Psychopharmacology (ASCP) Annual Meeting.
    • 01 Jun 2023 Results presented in a VistaGen Therapeutics media release Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top